Laboratory Lab results are too important to go anywhere else.

Hyperhomocysteinemia Genotyping for Thrombotic Risk Assessment - DISCONTINUED

Homocysteine genotyping, MTHFR genotyping, Hyperhomocysteinemia genotyping, Hyperhomocysteinemia (MTHFR) Genotyping

Effective Date:  1/24/2022

Instructions

Testing recommendations for MTHFR mutations have evolved and the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG) recommend against testing due to lack of predictive value for venous thromboembolism (VTE) or adverse pregnancy outcomes. There is growing evidence that disproves an association between hyperhomocysteinemia and risk for coronary heart disease and between MTHFR polymorphism status and risk for venous thromboembolism.

Supporting references:
1. ACMG Practice Guideline in Genetics in Medicine 2013; 15:153-156. 
2. ACOG Practice Bulletin Summary. Obstetrics & Gynecology 2018; 132: 249-251.

Due to these factors MTHFR genotyping will be discontinued and no Send Outs options are offered through Beaumont Laboratory.

Both Factor V Leiden (Test Code: LAB6383; CPT Code: 81241) and Factor II (Prothrombin) genotyping (Test Code: 6389; CPT Code: 81240) will continue to be offered at Beaumont Laboratory.

Test Discontinued
Hyperhomocysteinemia Genotyping for Thrombotic Risk Assessment (Homocysteine genotyping, MTHFR genotyping, Hyperhomocysteinemia genotyping, Hyperhomocysteinemia (MTHFR) Genotyping).

Test Code: LAB6386     CPT: 81291

Contacts

Last Updated

1/25/2022